In our survey, most experts used PSA-related factors such as PSA level, PSA doubling time and time from RP to biochemical progression as clinical surrogate parameters for adverse tumor biology as commonly done in other disease stages in prostate cancer [31, 32]. The gene discussed is KLK3; the disease is prostate carcinoma.